Kevin Weil’s Warp Sciences Raises $215M to Automate Drug Labs
Former OpenAI science lead Kevin Weil launches Warp Sciences with $215 million to automate drug-discovery wet labs using AI-trained robots around the clock.
Summary
Former OpenAI science lead Kevin Weil launched Warp Sciences on October 22, 2026, announcing on X that the AI drug-discovery startup raised $215 million at an $865 million valuation. Lightspeed led the round, joined by IVP, Premji Invest and Lux Capital. The company will train robots to make and test promising compounds identified by researchers.
Warp Sciences plans to automate labor-intensive wet-lab synthesis and testing now often outsourced by biotech companies to Chinese contractors such as WuXi AppTec, which produce thousands of molecular variations. Human chemists wearing cameras and sensor gloves will teach robots lab tasks, with machines intended to run around the clock, accelerate drug discovery, reshore work and reduce geopolitical supply-chain exposure. Customer, deployment and commercialization details remain limited.
Positives
- $215 million in funding gives Warp Sciences substantial capital to develop automated wet-lab systems.
- An $865 million valuation signals strong backing from Lightspeed, IVP, Premji Invest and Lux Capital.
- Around-the-clock robots could accelerate the production and testing of promising drug compounds.
- Reshoring laboratory work could reduce drug development’s exposure to geopolitical supply-chain disruptions.
Risks & concerns
- Thousands of molecular variations still require labor-intensive synthesis and testing during drug discovery.
- Chinese outsourcing through contractors such as WuXi AppTec creates geopolitical supply-chain exposure for biotech companies.
- Human chemists wearing cameras and sensor gloves must first teach the robots individual laboratory tasks.
- Customer names, deployment dates and commercialization plans have not been disclosed.